Home » Stocks » IQVIA Holdings

IQVIA Holdings Inc. (IQV)

Stock Price: $160.13 USD 0.49 (0.30%)
Updated Aug 11, 2020 3:28 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 30.63B
Revenue (ttm) 10.94B
Net Income (ttm) 132.00M
Shares Out 191.27M
EPS (ttm) 0.67
PE Ratio 238.99
Forward PE 26.04
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $160.13
Previous Close $159.64
Change ($) 0.49
Change (%) 0.30%
Day's Open 160.41
Day's Range 158.94 - 161.96
Day's Volume 474,632
52-Week Range 81.79 - 169.14

More Stats

Market Cap 30.63B
Enterprise Value 41.95B
Earnings Date (est) Oct 28, 2020
Ex-Dividend Date n/a
Shares Outstanding 191.27M
Float 189.78M
EPS (basic) 0.69
EPS (diluted) 0.67
FCF / Share 5.13
Dividend n/a
Dividend Yield n/a
Earnings Yield 0.42%
FCF Yield 3.20%
Payout Ratio n/a
Shares Short 2.49M
Short Ratio 2.07
Short % of Float 1.46%
Beta 1.33
PE Ratio 238.99
Forward PE 26.04
P/FCF Ratio 31.28
PS Ratio 2.80
PB Ratio 5.51
Revenue 10.94B
Operating Income 625.00M
Net Income 132.00M
Free Cash Flow 979.00M
Net Cash -11.33B
Net Cash / Share -59.22
Gross Margin 34.63%
Operating Margin 5.71%
Profit Margin 1.20%
FCF Margin 8.95%
ROA 1.97%
ROE 2.52%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (23)

Buy 18
Overweight 1
Hold 3
Underweight 1
Sell 0

Analyst Consensus: Buy

Price Target

$183.00*
(14.29% upside)
Low
140
Current: $160.13
High
204
Target: 183.00
*Average 12-month price target from 19 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue11,08810,4129,7026,8155,7375,4605,1004,8664,3283,924
Revenue Growth6.49%7.32%42.36%18.79%5.07%7.07%4.81%12.43%10.29%-
Gross Profit3,7883,6663,4012,0671,6211,5011,3371,2331,1421,119
Operating Income777741665576646590462396345395
Net Income1912591,27772.00387357227178242161
Shares Outstanding195204218149123128124116116116
Earnings Per Share0.961.245.740.473.082.721.771.512.051.36
EPS Growth-22.58%-78.4%1121.28%-84.74%13.24%53.67%17.22%-26.34%50.74%-
Operating Cash Flow1,4171,254970860476433393336161378
Capital Expenditures-582-459-369-164-78.00-83.00-86.33-68.61-72.70-77.68
Free Cash Flow83579560169639835030726788.25300
Cash & Equivalents8999381,0051,2389778707815715190.00
Total Debt12,04111,00710,2257,2002,4682,2832,0462,4221,972-
Net Cash / Debt-11,142-10,069-9,220-5,962-1,491-1,413-1,265-1,851-1,4530.00
Assets23,25122,54922,85721,2083,9263,2963,0672,4992,323-
Liabilities16,98815,59514,61312,3484,2624,0003,7343,8583,293-
Book Value6,0036,7147,9958,633-564-704-667-1,360-970-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name IQVIA Holdings Inc.
Country United States
Employees 67,000
CEO Ari Bousbib

Stock Information

Ticker Symbol IQV
Stock Exchange New York Stock Exchange
Unique Identifier NYSE: IQV
IPO Date May 9, 2013

Description

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support services; and strategic planning and design services, as well as clinical trial, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company has a strategic alliance with ACCORD-2 to provide single research platform to speed development of new COVID-19 treatments. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.